Proschak E - Search Results

1

Systematic Assessment of Fragment Identification for Multitarget Drug Design.

Brunst S, Kramer JS, Kilu W, Heering J, Pollinger J, Hiesinger K, George S, Steinhilber D, Merk D, Proschak E. Brunst S, et al. Among authors: proschak e. ChemMedChem. 2021 Apr 8;16(7):1088-1092. doi: 10.1002/cmdc.202000858. Epub 2021 Feb 4. ChemMedChem. 2021. PMID: 33283450 Free PMC article.

2

Scaffold-hopping cascade yields potent inhibitors of 5-lipoxygenase.

Hofmann B, Franke L, Proschak E, Tanrikulu Y, Schneider P, Steinhilber D, Schneider G. Hofmann B, et al. Among authors: proschak e. ChemMedChem. 2008 Oct;3(10):1535-8. doi: 10.1002/cmdc.200800153. ChemMedChem. 2008. PMID: 18688907 No abstract available.

3

PhAST: pharmacophore alignment search tool.

Hähnke V, Hofmann B, Grgat T, Proschak E, Steinhilber D, Schneider G. Hähnke V, et al. Among authors: proschak e. J Comput Chem. 2009 Apr 15;30(5):761-71. doi: 10.1002/jcc.21095. J Comput Chem. 2009. PMID: 18727161

4

From molecular shape to potent bioactive agents I: bioisosteric replacement of molecular fragments.

Proschak E, Zettl H, Tanrikulu Y, Weisel M, Kriegl JM, Rau O, Schubert-Zsilavecz M, Schneider G. Proschak E, et al. ChemMedChem. 2009 Jan;4(1):41-4. doi: 10.1002/cmdc.200800313. ChemMedChem. 2009. PMID: 19058279 No abstract available.

5

From molecular shape to potent bioactive agents II: fragment-based de novo design.

Proschak E, Sander K, Zettl H, Tanrikulu Y, Rau O, Schneider P, Schubert-Zsilavecz M, Stark H, Schneider G. Proschak E, et al. ChemMedChem. 2009 Jan;4(1):45-8. doi: 10.1002/cmdc.200800314. ChemMedChem. 2009. PMID: 19058280 No abstract available.

6

Homology model adjustment and ligand screening with a pseudoreceptor of the human histamine H4 receptor.

Tanrikulu Y, Proschak E, Werner T, Geppert T, Todoroff N, Klenner A, Kottke T, Sander K, Schneider E, Seifert R, Stark H, Clark T, Schneider G. Tanrikulu Y, et al. Among authors: proschak e. ChemMedChem. 2009 May;4(5):820-7. doi: 10.1002/cmdc.200800443. ChemMedChem. 2009. PMID: 19343764

7

Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1.

Keppner S, Proschak E, Schneider G, Spänkuch B. Keppner S, et al. Among authors: proschak e. ChemMedChem. 2009 Nov;4(11):1806-9. doi: 10.1002/cmdc.200900338. ChemMedChem. 2009. PMID: 19746360 No abstract available.

8

From machine learning to natural product derivatives that selectively activate transcription factor PPARgamma.

Rupp M, Schroeter T, Steri R, Zettl H, Proschak E, Hansen K, Rau O, Schwarz O, Müller-Kuhrt L, Schubert-Zsilavecz M, Müller KR, Schneider G. Rupp M, et al. Among authors: proschak e. ChemMedChem. 2010 Feb 1;5(2):191-4. doi: 10.1002/cmdc.200900469. ChemMedChem. 2010. PMID: 20043315 No abstract available.

9

Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription.

Steri R, Kara M, Proschak E, Steinhilber D, Schneider G, Schubert-Zsilavecz M. Steri R, et al. Among authors: proschak e. Future Med Chem. 2010 Apr;2(4):575-86. doi: 10.4155/fmc.10.10. Future Med Chem. 2010. PMID: 21426008

10

Potent inhibitors of 5-lipoxygenase identified using pseudoreceptors.

Rödl CB, Tanrikulu Y, Wisniewska JM, Proschak E, Schneider G, Steinhilber D, Hofmann B. Rödl CB, et al. Among authors: proschak e. ChemMedChem. 2011 Jun 6;6(6):1001-5. doi: 10.1002/cmdc.201100059. Epub 2011 Apr 19. ChemMedChem. 2011. PMID: 21506275 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

174 results

Search Page

Filters